US2024052003A1PendingUtilityA1

Compositions comprising pedf-derived short peptides (pdsp) and uses thereof

47
Assignee: BRIM BIOTECHNOLOGY INCPriority: Oct 6, 2019Filed: Dec 4, 2020Published: Feb 15, 2024
Est. expiryOct 6, 2039(~13.2 yrs left)· nominal 20-yr term from priority
Inventors:Frank Wen-Chi LeeWayne W.C. LiawPing HuangHsiao-Han Wang
C07K 14/435A61K 31/455A61K 31/4172A61K 47/10A61K 38/55A61K 9/08A61K 47/183A61K 47/22A61K 47/26A61K 38/1703
47
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

An aqueous formulation includes a PEDF-derived short peptide (PDSP) having the sequence of one of SEQ ID NO: 1, 2, 3, 5, 6, 8, or 9; histidine having a concentration of 1 mM-100 mM; and an antioxidant and optionally a non-ionic tonicity agent. The pH value is around 5-9. The antioxidant is nicotinamide, which is at a concentration of 50 mM-1000 mM. The non-ionic tonicity agent is sorbitol, which is at a concentration of 0 mM-500 mM. A concentration of the PDSP is 0.01%-1% w/v.

Claims

exact text as granted — not AI-modified
1 . An aqueous formulation, comprising:
 a PEDF-derived short peptide (PDSP) having the sequence of SEQ ID NO. 1, 2, 3, 5, 6, 8, or 9;   an antioxidant; and   histidine having a concentration of 1 mM-100 mM.   
     
     
         2 . The aqueous formulation of  claim 1 , wherein a pH value is around 5-9. 
     
     
         3 . The aqueous formulation of  claim 1 , wherein the antioxidant is nicotinamide. 
     
     
         4 . The aqueous formulation of  claim 3 , wherein a concentration of nicotinamide is 50 mM-1000 mM. 
     
     
         5 . The aqueous formulation of  claim 1 , further comprising a non-ionic tonicity agent. 
     
     
         6 . The aqueous formulation of  claim 5 , wherein the non-ionic tonicity agent is sorbitol. 
     
     
         7 . The aqueous formulation of  claim 6 , wherein a concentration of sorbitol is 0 mM-500 mM. 
     
     
         8 . The aqueous formulation of  claim 1 , wherein the concentration of histidine is 5 mM-60 mM. 
     
     
         9 . The aqueous formulation of  claim 1 , wherein the concentration of histidine is 10 mM-40 mM. 
     
     
         10 . The aqueous formulation of  claim 1 , wherein the PDSP has the sequence of SEQ ID NO:3. 
     
     
         11 . The aqueous formulation of  claim 10 , wherein a concentration of the PDSP is 0.01%-1% w/v. 
     
     
         12 . The aqueous formulation of  claim 2 , wherein the PDSP has the sequence of SEQ ID NO:3. 
     
     
         13 . The aqueous formulation of  claim 3 , wherein the PDSP has the sequence of SEQ ID NO:3. 
     
     
         14 . The aqueous formulation of  claim 4 , wherein the PDSP has the sequence of SEQ ID NO:3. 
     
     
         15 . The aqueous formulation of  claim 5 , wherein the PDSP has the sequence of SEQ ID NO:3. 
     
     
         16 . The aqueous formulation of  claim 6 , wherein the PDSP has the sequence of SEQ ID NO:3. 
     
     
         17 . The aqueous formulation of  claim 7 , wherein the PDSP has the sequence of SEQ ID NO:3. 
     
     
         18 . The aqueous formulation of  claim 8 , wherein the PDSP has the sequence of SEQ ID NO:3. 
     
     
         19 . The aqueous formulation of  claim 9 , wherein the PDSP has the sequence of SEQ ID NO:3.

Join the waitlist — get patent alerts

Track US2024052003A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.